Mitral valve disease takes many different forms: mitral valve prolapse, annular enlargement, leaflet tethering, papillary muscle extension and leaflet tearing (see Fig. 1). All of these conditions result in leakage of the valve in its closed position, i.e. mitral regurgitation (MR), which can lead to heart failure. We are developing an easy to implant device that will treat MR in patients with moderate to severe mitral valve disease.
What Problem Does it Solve/Advantages
Clinical Need & Potential Market - Statistical Overview
- Incidence of valvular heart disease in the US is approximately 2.5% of the population [Nkomo et al Lancet 2006].
- Mitral valve disease (MVD) is the most common form of heart valve disease consisting of 1.7% of the 2.5%.
- Approximately 3.5 million American citizens currently have mitral valve disease [Nkomo et al Lancet 2006].
- Mortality rate during the surgical procedure for patients over the age of 75 is approximately 25% [Rajendra et al Ann Thor Surg 2002].
- Approximately 9% of US citizens over the age of 75 have mitral valve disease [Marelli et al Circ 2007]. UN population prospects indicate that the number of people aged over 75 in the developed world is estimated to increase by 40% in the period between 2000 and 2020 [UN World Population Prospects: The 2008 Revision]
- The transcatheter mitral valve market is approximately a $1-2Bn opportunity.
Our concept is a transcatheter based device for the treatment of a diseased Mitral Valve (MV), used for both MV repair and replacement.
Presently the inventive step and novelty arguments are progressing and current feedback is very positive.
he priority date on this technology is Jan 2011, whereby a European Patent application was filed.
Dr. Bruce Murphy, Dr. Liam Breen Dr. Gillian Gunning
Technology Transfer Case Manager: Dr Gordon Elliott